Mumps and mumps vaccine: A global review

Bulletin of the World Health Organization

Volumn 77, Issue 1, 1999, Pages 3-14

  Galazka, A M ^a   Robertson, S E ^b   Kraigher, A ^c  

^a NATIONAL INSTITUTE OF HYGIENE   (Poland)

^b WORLD HEALTH ORGANIZATION   (Switzerland)

^c NATIONAL INSTITUTE OF PUBLIC HEALTH   (Slovenia)

Author keywords

[No Author keywords available]

Indexed keywords

MEASLES MUMPS RUBELLA VACCINE; MEASLES MUMPS VACCINE; MUMPS VACCINE;

DISEASE CONTROL; GLOBAL PERSPECTIVE; INFECTIOUS DISEASE; VACCINATION;

CLINICAL FEATURE; DRUG CHOICE; DRUG EFFICACY; DRUG SAFETY; GEOGRAPHIC DISTRIBUTION; HEARING IMPAIRMENT; HUMAN; IMMUNOGENICITY; INFECTION CONTROL; MUMPS; MUMPS VIRUS; ORCHITIS; PANCREATITIS; PREVENTIVE HEALTH SERVICE; REVIEW; TREATMENT OUTCOME; VACCINATION; VIRUS ENCEPHALITIS; VIRUS STRAIN;

DELIVERY OF HEALTH CARE; DISEASES; EPIDEMIOLOGY; HEALTH; HEALTH SERVICES; IMMUNIZATION; MORBIDITY; PRIMARY HEALTH CARE; PUBLIC HEALTH; SAFETY; VACCINATION; VACCINES; VIRAL DISEASES; WORLD;

ADULT; CHILD; FEMALE; HUMANS; INCIDENCE; MALE; MUMPS; MUMPS VACCINE; PREGNANCY; WORLD HEALTH;

EID: 0033013773     PISSN: 00429686     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (92)

1. th edit. London, Churchill Livingston, 1995: 1496-1501.
2. Beard CM et al. The incidence and outcome of mumps orchitis in Rochester, Minnesota, 1935 to 1974. Mayo Clinic proceedings, 1977, 52: 3-7.
3. Swerdlow AJ, Huttly SRA, Smith PG. Testicular cancer and antecedent diseases. British journal of cancer, 1987, 55: 97-103.
4. Philip RN, Reinhard KR, Lackman DB. Observations on a mumps epidemic in a "virgin" population. American journal of hygiene, 1959, 69: 91-111.
5. Siegel M, Fuerst HT, Peress NS. Comparative fetal mortality in maternal virus diseases: a prospective study on rubella, measles, mumps, chicken pox and hepatitis. New England journal of medicine, 1966, 274: 768-771.
6. Siegel M. Congenital malformations following chickenpox, measles, mumps and hepatitis: results of a cohort study. Journal of the American Medical Association, 1973, 226: 1521-1524.
7. Falk WA et al. The epidemiology of mumps in southern Alberta, 1980-1982. American journal of epidemiology, 1989, 130: 736-749.
8. Stratton KR, Howe CJ, Johnston RB, eds. Adverse events associated with_childhood vaccines: evidence bearing on causality. Washington, DC, National Academy Press, 1994: 155-159.
9. Bang HO, Bang J. Involvement of the central nervous system in murrps. Acta medica scandinavica, 1943, 113: 487-505.
10. nd edit. Oxford, Oxford University Press, 1993.
11. Bjorvatn B, Skoldenberg B. Mumps and its complications in Stockholm. British medical journal, 1979, 1: 788.
12. Russell RR, Donald JC. The neurological complications of mumps. British medical journal, 1958, 2: 27-30.
13. Mumps surveillance, January 1972-June 1974. Atlanta, USA, Center for Disease Control, 1974 (DHEW Publication No. CDC 75-8178).
14. Xu Y et al. Viral etiology of acute childhood encephalitis in Beijing diagnosed by analysis of single samples. Pediatric infectious disease journal, 1996, 15: 1018-1024.
15. Vuori M, Lahikainen EA, Peltonen T. Perceptive deafness in connection with mumps: a study of 298 servicemen suffering from mumps. Acta otolaryngology, 1962, 55: 231-236.
16. Hall R, Richards H. Hearing loss due to mumps. Archives of disease in childhood, 1987, 62: 189-191.
17. Minja BM. Aetiology of deafness among children at the Buguruni School for the Deaf in Dar es Salaam, Tanzania. International journal of pediatric otorhinolaryngology, 1998, 42: 225-231.
18. Utz JP, Houk VN, Alling DW. Clinical and laboratory studies of mumps. IV. Viruria and abnormal renal function. New England journal of medicine, 1964, 270: 1283-1286.
19. Lin CY, Chen WP, Chiang H. Mumps associated with nephritis. Child nephrology and urology, 1990, 10: 68-71.
20. Rosenberg DH. Electrocardiographic changes in epidemic parotitis (mumps). Proceedings of the Society for Experimental Biology and Medicine, 1945, 58: 9-11.
21. Özkutlu S et al. Fatal mumps myocarditis. Japanese heart journal, 1989, 30: 109-114.
22. Galbraith NS et al. Mumps surveillance in England and Wales 1962-81. Lancet, 1984, 1: 91-94.
23. Hirsch A. Mumps (Parotitis epidemica s. polymorpha). In: Handbook of geographical and historical pathology, vol III. London, New Syndenham Society, 1886: 277-283.
24. Levitt LP et al. Mumps in a general population: a seroepidemiologic study. American journal of diseases of children, 1970, 120: 134-138.
25. Gordon JE, Kilham L. Ten years in the epidemiology of mumps. American journal of medical science, 1949, 218: 338-359.
26. Slater PE, Roitman M, Costin C. Mumps incidence in Israel - impact of MMR vaccine. Public health reviews, 1991, 18: 88-93.
27. Sato H, et al. Transfer of measles, mumps, and rubella antibodies from mother to infant: its effect on measles, mumps, and rubella immunization. American journal of diseases of children, 1979, 133: 1240-1243.
28. Morgan-Capner P et al. Surveillance of antibody to measles, mumps, and rubella by age. British medical journal, 1988, 297: 770-772.
29. Wagenvoort JHT et al. Epidemiology of mumps in the Netherlands. Journal of hygiene, 1980, 85: 313-326.
30. Seroepidemiology of measles, mumps and rubella, Singapore. Weekly epidemiological record, 1992, 67(31): 231-233.
31. Cox MJ et al. Seroepidemiological study of the transmission of the mumps virus in St. Lucia, West Indies. Epidemiology and infection, 1989, 102: 147-160.
32. Bakir TMF et al. Seroepidemiology of mumps, measles, and subacute sclerosing panencephalitis in Saudi Arabia. Journal of tropical pediatrics, 1988, 34: 254-256.
33. Imbs D, Loza-Tulimowska M, Rudnicka H. [Occurrence of antibodies against mumps in the population of Poland]. Przeglad epidemiologiczny, 1984, 38: 361-368 (in Polish).
34. WHO Expert Committee on Biological Standardization. Forty-third report. Geneva, World Health Organization, 1994 (WHO Technical Report Series No. 840).
35. Recommendations of the Immunization Practices Advisory Committee. Measles, mumps, and rubella - vaccine use and strategies for elimination of measles, rubella, and congenital rubella syndrome and control of mumps. Morbidity and mortality weekly report, 1998, 47 (RR-8): 1-57.
36. Juntunen-Backman K et al. Safe immunization of allergic children against measles, mumps, and rubella. American journal of diseases of children, 1987, 141: 1103-1105.
37. James JM et al. Safe administration of the measles vaccine to children allergic to eggs. New England journal of medicine, 1995, 332: 1262-1266.
38. Kelso JM, Jones RT, Yunginger JW. Anaphylaxis to measles, mumps, and rubella vaccine mediated by IgE to gelatin. Journal of allergy and clinical immunology, 1993, 91: 867-872.
39. Kwittken PL, Rosen S, Sweinberg SK. MMR vaccine and neomycin allergy. American journal of diseases of children, 1993, 147: 128-129.
40. Buynak EB, Hilleman MR. Live attenuated mumps virus vaccine: 1. Vaccine development. Proceedings of the Society for Experimental Biology and Medicine, 1966, 123: 768-775.
41. Fahlgren K. Two doses of MMR vaccine - sufficient to eradicate measles, mumps and rubella? Scandinavian journal of social medicine, 1988, 16: 129-135.
42. Broliden K et al. Immunity to mumps before and after MMR vaccination at 12 years of age in the first generation offered the two-dose immunization programme. Vaccine, 1997, 16: 323-327.
43. Davidkin I, Valle M, Julkunen I. Persistence of anti-mumps virus antibod es after a two-dose MMR vaccination: a nine-year follow-up. Vaccine, 1995, 13: 1617-1622.
44. nd edit. Philadelphia, PA, WB Saunders, 1994: 277-301.
45. Briss PA et al. Sustained transmission of mumps in a highly vaccinated population: assessment of primary vaccine failure and waning vaccine-induced immunity. Journal of infectious diseases, 1994, 169: 77-82.
46. Hersh BS et al. Mumps outbreak in a highly vaccinated population. Journal of pediatrics, 1991, 119: 187-193.
47. Ehrenkranz NJ et al. Clinical evaluation of a new measles-mumps-rubella combined live virus vaccine in the Dominican Republic. Bulletin of the World Health Organization, 1975, 52: 81-85.
48. Black S et al. Risk of hospitalization because of asept c meningitis after measles-mumps-rubella vaccination r one-to two-year-old children: an analysis of the Vaccine Safety Datalink (VSD) Project. Pediatric infectious disease journal, 1997, 16: 500-503.
49. Fescharek R et al. Measles-mumps vaccination in the FRG: an empirical analysis after 14 years of use. II. Tolerability and analysis of spontaneously reported side-effects. Vaccine, 1990, 8: 446-456.
50. Smorodintsev AA, Nasibov MN, Jakovleva NV. Experience w th live rubella virus vaccine combined with live vaccines against measles and mumps. Bulletin of the World Health Organization, 1970, 42: 283-289.
51. Unanov SS et al. [Results of studying a live mumps vaccine from strain L-3 manufactured by the Moscow Research Institute of Viral Preparations: the epidemiological effectiveness of the vaccine]. Voprosy Virusologii, 1977, 1: 59-61 (in Russian).
52. Kraigher A. [Monitoring side-effects and adverse events following immunization against measles and mumps in a national vaccination programme in Slovenia from 1982 to 1986]. Dissertation, Medical Faculty, Zagreb, Croatia, 1990 (in Sloveniar).
53. Cizman M et al. Aseptic meningitis after vaccination against measles and mumps. Pediatric infectious disease journal, 1989, 8: 302-308.
54. Beck M et al. Mumps vaccine L-Zagreb, prepared in chick fibroblasts: I. production and field trials. Journal of biological standardization, 1989, 17: 85-90.
55. Bhargava I et al. Immunogenicity and reactogenicity of indigenously produced MMR vaccine. Indian pediatrics, 1995, 32: 983-988.
56. Tesovic G, Begovac J, Bace A. Aseptic meningitis after measles, mumps, and rubella vaccine. Lancet, 1993, 341: 1541.
57. Gluck R et al. Rubini, a new live attenuated mumps vaccine virus strain for human diploid cells. Developments in biological standardization, 1986, 65: 29-35.
58. Schwarzer S et al. Safety and characterization of the immune response engendered by two combined measles, mumps aid rubella vaccines. Vaccine, 1998, 16: 298-304.
59. Chamot E, et al. [Estimation of the efficacy of three strains of mumps vaccine during an outbreak in Geneva State (Switzerland)]. Epidemiology and public health, 1998, 46: 100-107 (in French).
60. Paccaud MF et al. [Two mumps outbreaks in retrospect]. Sozial- und Präventivmedizin, 1995, 40: 72-79 (in German).
61. Toscani L et al. Comparaison de l'efficacité de différentes souches ce vaccin ourlien: une enquête en milieu scolaire. Sozial- und Präventivmedizin, 1996, 41: 1-7.
62. Benevento and Compobasso Pediatricians Network for the Control of Vaccine-Preventable Diseases. Field evaluation of the clinical effectiveness of vaccines against pertussis, measles, rubella and mumps. Vaccine, 1998, 16: 818-822.
63. Dias JA et al. Mumps epidemic in Portugal despite high vaccine coverage - preliminary report. Eurosurveillance, 1996, 1: 25-28.
64. Vesikari T et al. Evaluation in young children of the Urabe Am 9 strain of live attenuated mumps vaccine in comparison with the Jeryl Lynn strain. Acta paediatrica Scandinavia, 1983, 72: 37-40.
65. Forleo-Neto E et al. Seroconversion of a trivalent measles, mumps, and rubella vaccine in children aged 9 and 15 months. Vaccine, 1997, 15: 1898-1901.
66. Schoub BD et al. Measles, mumps and rubella immunization at nine months in a developing country. Pediatric infectious disease journal, 1990, 9: 263-267.
67. Singh R et al. Immune response to measles, mumps & rubella vaccine at 9, 12 & 15 months of age. Indian journal of medical research, 1994, 100: 155-159.
68. Huang L-M et al. Effect of monovalent measles and trivalent measles-mumps-rubella vaccines at various ages and concurrent administration with hepatitis B vaccine. Pediatric infectious disease journal, 1990, 9: 461-465.
69. Miller E et al. Antibodies to measles, mumps and rubella in UK children 4 years after vaccination with different MMR vaccines. Vaccine, 1995, 13: 799-802.
70. Boulianne N et al. Measles, mumps, and rubella antibodies in children 5-6 years after immunization: effect of vaccine type and age of vaccination. Vaccine, 1995, 13: 1611-1616.
71. Brown EG, Dimock K, Wright KE. The Urabe AM9 mumps vaccine is a mixture of viruses differing at amino acid 335 of the hemagglutinin-neuraminidase gene with one form associated with disease. Journal of infectious diseases, 1996, 174: 619-622.
72. Furesz J, Contreras G. Vaccine-related mumps meningitis - Canada. Canadian diseases weekly report, 1990, 16(50): 253-254.
73. Miller E et al. Risk of aseptic meningitis after measles, mumps, and rubella vaccine in UK children. Lancet, 1993, 341: 979-982.
74. Sugiura A, Yamada A. Aseptic meningitis as a complication of mumps vaccination. Pediatric infectious disease journal, 1991, 10: 209-213.
75. Ueda K et al. Aseptic meningitis caused by measles-mumps-rubella vaccine in Japan. Lancet, 1995, 346: 701-702.
76. Robertson SE et al. Control of rubella and congenital rubella syndrome (CRS) in developing countries, part 2: vaccination against rubella. Bulletin of the World Health Organization, 1997, 75: 69-80.
77. WHO Division of Health Situation and Trend Assessment. Demographic data for health situation assessment and projections. Geneva, World Health Organization, 1996.
78. De Serres G et al. Epidemiology of mumps in Quebec, 1970-1995. Canada communicable disease report, 1997, 23(2): 1-4.
79. van Loon FPL et al. Mumps surveillance - United States, 1988-1993. Morbidity and mortality weekly report, 1995, 44, SS-3, 1-14.
80. WHO Regional Office for Europe. Operational targets for EPI diseases. Unpublished document EUR/ICP/CMDS 01 01 14 Rev. 1. Copenhagen, World Health Organization, 1996.
81. Health for all database. Copenhagen, WHO Regional Office for Europe, 1998.
82. Bakasun V. Mumps in the region of Rijeka, Croatia. European journal of epidemiology, 1997, 13: 117-119.
83. Gay N et al. Mumps surveillance in England and Wales supports introduction of a two dose vaccination schedule. Communicable disease report, 1997, 7: R21-R26.
84. Peltola H et al. The elimination of indigenous measles, mumps, and rubella from Finland by a 1-year, two-dose vaccination program. New England journal of medicine, 1994, 331: 1397-1402.
85. Koskiniemi M, Vaheri A. Effect of measles, mumps, rubella vaccination on pattern of encephalitis in children. Lancet, 1989, 1:31-34
86. Darin N, Hanner P, Thiringer K. Changes in prevalence, aetiology, age at detection, and associated disabilities in preschool children with hearing impairment born in Göteborg. Developmental medicine and child neurology, 1997, 39: 797-802.
87. Topal B, Kanra G, Ceyhan M. Serological evaluation of 52 children immunized with the combined measles, mumps and rubella vaccine. Turkish journal of pediatrics, 1991, 33: 13-18.
88. Expanded Programme on Immunization. framework for evaluating a vaccine for the EPI. Unpublished document WHO/ EPI/GEN/93.5. Available upon request from Director, Global Programme for Vaccines and Immunization, World Health Organization, 1211 Geneva 27, Switzerland.
89. Meningitis associated with measles-mumps-rubella vaccines. Weekly epidemiological record, 1992, 67(41) : 301-302; and 1992, 67(51/52): 387.
90. Meningitis associated with measles-mumps-rubella vaccines. Weekly epidemiological record, 1992, 67(41) : 301-302; and 1992, 67(51/52): 387.
91. Wiedermann G, Ambrosch F. Cost-benefit calculations of vaccinations against measles and mumps in Austria. Developments in biological standardization, 1978, 43: 273-277.
92. Berger SA, Ginsberg GM, Slater PE. Cost-benefit analysis of routine mumps and rubella vaccination for Israeli infants. Israel journal of medical sciences, 1990, 26: 74-80.